

## **Study Synopsis**

# **In situ mineral change and fluoride retention of sound and demineralized enamel in high cariogenic milieus following the single application of a 1.25%-fluoride or a placebo gel.**

**GABA Study Number: GASAS-0809X**

**EUDRACT Number: 2008-008594-58**

**Collaboration Centre:**

Department of Operative Dentistry and Periodontology  
School of Dentistry  
University Hospital Freiburg  
Hugstetter Straße 55  
D-79106 Freiburg  
Prof. Dr. Elmar Hellwig

**Sponsor:**

GABA International AG  
Grabetsmattweg  
CH-4106 Therwil

**SYNOPSIS**

Name of Sponsor / Company: GABA International AG	Individual Study Table Referring to Part of the Dossier	(For National Authority Use Only)
Name of Product: elmex gel (elmex gelée)	Volume:	
Name of Active Ingredient: Amine fluoride Olaflur 0,23 % F <sup>-</sup>  Amine fluoride Dectaflur 0,02 % F <sup>-</sup>  Sodium fluoride 1,00 % F <sup>-</sup>	Page 51	
<b>Title of the Study:</b>  In situ mineral change and fluoride retention of sound and demineralized enamel in high cariogenic milieus following the single application of a 1.25%-fluoride or a placebo gel.		
<b>Investigators:</b>  Prof. Dr. Elmar Hellwig  Dr. Markus Altenburger		
<b>Study Centre:</b>  Department of Operative Dentistry and Periodontology School of Dentistry University Hospital Freiburg Hugstetter Straße 55 D-79106 Freiburg		
<b>Publication (references):</b>  Not published yet		

Name of Sponsor / Company: GABA International AG	Individual Study Table Referring to Part of the Dossier	(For National Authority Use Only)
Name of Product: elmex gel (elmex gelée)	Volume:	
Name of Active Ingredient: Amine fluoride Olaflur 0,23 % F <sup>-</sup>	Page 51	
Amine fluoride Dectaflur 0,02 % F <sup>-</sup>		
Sodium fluoride 1,00 % F <sup>-</sup>		
Study period: Date of first enrolment: 23.9.2009 Date of last completed: 11.3.2010	Phase of Development: IV	
<b>Objectives:</b> Evaluation of the mineral change, change of the lesion depth and change of the fluoride content in sound and demineralized enamel specimens after a single tray application of elmex gel or placebo and subsequent high cariogenic conditions.		
<b>Methodology:</b> Transverse microradiography - TMR Fluoride content measurement		
<b>Number of Subjects (planned and analyzed):</b> Planned 36, analyzed 38 safety analysis/ 36 efficacy analysis		
<b>Diagnosis and main criteria for inclusion:</b> Healthy subjects matching inclusion, not violating exclusion criteria.		
<b>Test product, dose and mode of administration, batch number:</b> elmex gel (elmex gelée), 7 g, intraoral tray application, topical on oral mucosa		

Name of Sponsor / Company: GABA International AG	Individual Study Table Referring to Part of the Dossier	(For National Authority Use Only)
Name of Product: elmex gel (elmex gelée)	Volume:	
Name of Active Ingredient: Amine fluoride Olaflur 0,23 % F <sup>-</sup>  Amine fluoride Dectaflur 0,02 % F <sup>-</sup>  Sodium fluoride 1,00 % F <sup>-</sup>	Page 51	
<b>Duration of treatment:</b>  4 Minutes		
<b>Reference therapy, dose and mode of administration, batch number:</b>  placebo gel , 7 g , intraoral tray application, topical on oral mucosa		
<b>Criteria for evaluation:</b>  <b>Efficacy:</b> Change of mineral content, change of lesion depth, change of fluoride content of sound and demineralized enamel specimens  <b>Safety:</b> Recording and analysis of adverse events		
<b>Statistical methods:</b>  Paired t-test		

Name of Sponsor / Company: GABA International AG	Individual Study Table Referring to Part of the Dossier	(For National Authority Use Only)
Name of Product: elmex gel (elmex gelée)	Volume:	
Name of Active Ingredient: Amine fluoride Olaflur 0,23 % F <sup>-</sup>	Page 51	
Amine fluoride Dectaflur 0,02 % F <sup>-</sup>		
Sodium fluoride 1,00 % F <sup>-</sup>		
<p><b>Summary – Conclusions:</b></p> <p><b>Efficacy Results:</b></p> <p>The treatment of sound enamel specimens with elmex gel prior to the exposition to high cariogenic condition led to a statistically significantly lower demineralization compared to sound specimens that were treated with a placebo gel (<math>p &lt; 0.001</math>). Also the lesion depth increased significantly lower in the elmex gel group compared to the placebo group (<math>p &lt; 0.001</math>). No statistically significant difference could be found after measuring the fluoride content. In both groups higher fluoride levels were measured but these were not statistically significant.</p> <p>The application of elmex gel on demineralized enamel specimens prior to an exposition to a high cariogenic environment led to a deposition of minerals in the lesion, whereas treatment with placebo led to further demineralization. The same effect was observed for the lesion depth. Treatment with elmex gel decreases, treatment with the placebo gel increases the lesion size. Both analyzed parameters are statistically significant different from each other.</p> <p>In both groups, , the treatment with elmex gel or placebo gel led to a higher fluoride content in sound and demineralized enamel. However these values were not statistically significant from each other.</p>		

Name of Sponsor / Company: GABA International AG	Individual Study Table Referring to Part of the Dossier	(For National Authority Use Only)
Name of Product: elmex gel (elmex gelée)	Volume:	
Name of Active Ingredient: Amine fluoride Olaflur 0,23 % F <sup>-</sup>	Page 51	
Amine fluoride Dectaflur 0,02 % F <sup>-</sup>		
Sodium fluoride 1,00 % F <sup>-</sup>		
<p><b>Safety Results:</b></p> <p>18 adverse events (AE) were observed of which three cases were classified as ‘definite’ in relation to a possible causality of its occurrence and the study product. The symptoms of these three adverse events were ‘burning feeling’ in the oral cavity and ablation of the oral mucosa.</p> <p>No serious adverse event (SAE) was observed.</p>		
<p><b>Conclusion:</b></p> <p>With the present results it can be concluded that elmex gelée induces a remineralization of demineralized enamel or at least hampers demineralization of enamel even under high cariogenic conditions. It can be recommended for caries prevention in ‘high risk groups’. The observed adverse symptoms have already been described in literature and must be taken into consideration when this product is applied.</p>		
<p><b>Date of report:</b> 17.11.2011</p>		